TD Cowen says that in response to the legal action taken against the FDA by the Outsourcing Facilities Association on the removal of tirzepatide off the shortage list, FDA proposed
TD Cowen says that in response to the legal action taken against the FDA by the Outsourcing Facilities Association on the removal of tirzepatide off the shortage list, FDA proposed
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of $28.00. The company’s shares closed
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Spirit Airlines (SAVE) has entered into Chapter 11 bankruptcy
Hims & Hers Health, announced Deb Autor, former deputy commissioner at the FDA, will join the company’s board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts during the